Trending...
- wine2wine Vinitaly Business Forum 2025: Equipping the wine industry with the tools to face an uncertain future - 151
- September Career Reset - How Job Seekers Are Using WIOA to Pivot Before Year-End - 121
- CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs - 116
CHICAGO, Oct. 31, 2024 ~ Amphix Bio, a leading company in the development of regenerative medicine therapies, has announced that it has been awarded a $1 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF). The grant will be used to scale up manufacturing methods for the company's innovative platform technology, which is based on supramolecular peptide therapeutics that signal the patient's own cells to initiate regenerative processes.
The main focus of this grant is to develop manufacturing technology that will enable Amphix Bio to produce an off-the-shelf implant for spinal fusion surgeries. This product has recently been designated as a Breakthrough Device by the FDA for its potential in treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio successfully developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that showed promising results in large animal models. With this Phase II grant, the company aims to further scale up production of their therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
More on illi News
According to Amphix Bio co-founder and CEO Nick Sather, PhD, "We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic." He also added that their technology has the potential to offer a simpler and safer solution for treating debilitating back pain without any side effects associated with traditional methods such as harvesting autograft tissue or using recombinant proteins.
In preparation for clinical trials, Amphix Bio has recently expanded its team with new hires in manufacturing and operations. Dr. Iwona Maciagiewicz joined the company last year and brings extensive experience in biotech manufacturing including small molecules, biologics, and diagnostic devices. Dr. Hussain Sangji also joined Amphix Bio in 2024 from the Boston Consulting Group (BCG) and will be leading strategy and operations projects for major global Biopharma and MedTech companies.
More on illi News
This grant brings Amphix Bio's total SBIR funding to $1.25 million. In addition to the SBIR grant, the company has also received non-dilutive funding from the Illinois Science and Technology Coalition to support innovation in the state. These grants will further expand Amphix Bio's collaborations with Northwestern University. The company will be working closely with Dr. Wellington Hsu, MD, and Dr. Erin Hsu, PhD, professors of orthopedic surgery at Northwestern's Feinberg School of Medicine, who will oversee pre-clinical testing and advise on the clinical development of the product.
With this new grant funding and strengthened team, Amphix Bio is well-positioned to advance their innovative regenerative medicine therapies towards clinical trials and potentially revolutionize the treatment of back pain caused by degenerative disc disease.
The main focus of this grant is to develop manufacturing technology that will enable Amphix Bio to produce an off-the-shelf implant for spinal fusion surgeries. This product has recently been designated as a Breakthrough Device by the FDA for its potential in treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio successfully developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that showed promising results in large animal models. With this Phase II grant, the company aims to further scale up production of their therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
More on illi News
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
According to Amphix Bio co-founder and CEO Nick Sather, PhD, "We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic." He also added that their technology has the potential to offer a simpler and safer solution for treating debilitating back pain without any side effects associated with traditional methods such as harvesting autograft tissue or using recombinant proteins.
In preparation for clinical trials, Amphix Bio has recently expanded its team with new hires in manufacturing and operations. Dr. Iwona Maciagiewicz joined the company last year and brings extensive experience in biotech manufacturing including small molecules, biologics, and diagnostic devices. Dr. Hussain Sangji also joined Amphix Bio in 2024 from the Boston Consulting Group (BCG) and will be leading strategy and operations projects for major global Biopharma and MedTech companies.
More on illi News
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- Simpli.fi Earns Finalist Honors in the 2025 AdExchanger Awards
- Cyrus O'Leary's Introduces Cookie Dough Pybrid for Foodservice, Giving Chefs a Blank Canvas for Signature Desserts
This grant brings Amphix Bio's total SBIR funding to $1.25 million. In addition to the SBIR grant, the company has also received non-dilutive funding from the Illinois Science and Technology Coalition to support innovation in the state. These grants will further expand Amphix Bio's collaborations with Northwestern University. The company will be working closely with Dr. Wellington Hsu, MD, and Dr. Erin Hsu, PhD, professors of orthopedic surgery at Northwestern's Feinberg School of Medicine, who will oversee pre-clinical testing and advise on the clinical development of the product.
With this new grant funding and strengthened team, Amphix Bio is well-positioned to advance their innovative regenerative medicine therapies towards clinical trials and potentially revolutionize the treatment of back pain caused by degenerative disc disease.
Filed Under: Business
0 Comments
Latest on illi News
- Vinitaly International Academy welcomes Guido Berlucchi & C. SpA once again as Educational Supporter for its 33rd Certification Course
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
- NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
- Sci-Fi Author Don Viecelli Introduces Alien Times - Book 3, Retribution
- Poncho Tha Popstar: The West's Next King
- Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers
- Thorn Ridge® Creates a World of Legends & Lore
- Twice the Laughs: Comedy Star Don Barnhart Rotates Residency at Both Delirious Comedy Club Locations in Las Vegas
- Faith Center Freeport Hosts DJ Lyfe's Music Launch Event
- Schneider Electric Reinforces Commitment to Electrical Contractors with Innovation and Thought Leadership at NECA 2025
- Your Body Isn't Broken—It's Out of Balance: The New Book Revealing the Blueprint to Restore Hormone Balance, Sleep, Gut & Metabolic Health
- Chicago: Mayor Brandon Johnson Celebrates 10-Year Anniversary Of Dyett High School Hunger Strike
- Mayor Brandon Johnson Launches Protecting Chicago Website
- Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
- How Rising Property Taxes Are Pushing Families Toward Foreclosure --4Closure Rescue LLC Responds
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025
- Prostate Cancer Survivor's Podcast Grows Audience And Builds Marketing Muscle
- CCHR, a Mental Health Watchdog Organization, Hosts Weekly Events Educating Citizens on Important Mental Health Issues